Dapsone-induced motor polyneuropathy. A complication of prolonged treatment of subcorneal pustular dermatosis.
A motor polyneuropathy developed in a woman with subcorneal pustular dermatosis of 16 years' duration, who had received at least 300 gm of dapsone over a five-year period and 80 gm during the four-month period of progression of her neurologic symptoms. Although the patient believed her muscle power had returned to normal four months after the drug was stopped, a slight peripheral neuropathy remained. Electrodiagnostic and clinical features during the period of greatest weakness and the subsequent 16 months were consistent with a polyneuropathy of the axonal type. The neurotoxicity of dapsone appears to be dose-dependent, but the mechanism by which it occurs is unknown.
D000328:Adult; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D009046:Motor Neurons; D009410:Nerve Degeneration; D009468:Neuromuscular Diseases / Q000139:chemically induced*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011241:Prednisone / Q000627:therapeutic use; D012871:Skin Diseases / Q000188:drug therapy* / Q000473:pathology; D013427:Sulfapyridine / Q000627:therapeutic use
D003622:Dapsone; D011241:Prednisone; D013427:Sulfapyridine